Fig. 7
From: Challenges and new technologies in adoptive cell therapy
Anti-tumor mode of CAR-γδT and CAR-NKT cell therapies. Both CAR-γδT and CAR-NKT cells can kill tumor cells through CAR-, ADCC-, Fas/FasL-, TRAIL-, and TNFR-mediated ways and can mobilize other immune cells by secreting cytokines. CAR-γδT cells can also be activated with select receptors, whereas the activating receptor of CAR-NKT cells is limited to CD1d. Furthermore, CAR-γδT cells can present antigens to T cells, and CAR-NKT cells can promote DC maturation and be activated by DCs. TAA, tumor-associated antigen; ADCC, FasL, Fas ligand; TRAILR, TRAIL receptor; TNFR, TNF receptor; TCR, T cell receptor; iTCR, invariant T cell receptor; CD40L, CD40 ligand; and DC, dendritic cell